Humedix Co., Ltd. (200670.KQ)
- Previous Close
40,050.00 - Open
40,100.00 - Bid 40,550.00 x --
- Ask 40,600.00 x --
- Day's Range
39,900.00 - 41,100.00 - 52 Week Range
25,400.00 - 46,450.00 - Volume
41,094 - Avg. Volume
107,994 - Market Cap (intraday)
420.08B - Beta (5Y Monthly) 0.52
- PE Ratio (TTM)
-- - EPS (TTM)
-- - Earnings Date May 8, 2025 - May 12, 2025
- Forward Dividend & Yield 660.00 (1.65%)
- Ex-Dividend Date Mar 28, 2025
- 1y Target Est
54,000.00
Humedix Co., Ltd. engages in the manufacture and sale of various pharmaceutical products in South Korea. The company offers prescription medicines, active pharmaceutical ingredients, medical devices, cosmetic, and health functional food products. It is also involved in manufacture and distribution of anticancer drugs. The company was formerly known as HVLS Co., Ltd. and changed its name to Humedix Co., Ltd. in 2010. Humedix Co., Ltd. was founded in 2002 and is headquartered in Seongnam-si, South Korea.
humedix.com--
Full Time Employees
December 31
Fiscal Year Ends
Sector
Recent News: 200670.KQ
View MorePerformance Overview: 200670.KQ
Trailing total returns as of 5/2/2025, which may include dividends or other distributions. Benchmark is KOSPI Composite Index (^KS11) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: 200670.KQ
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: 200670.KQ
View MoreValuation Measures
Market Cap
412.86B
Enterprise Value
305.50B
Trailing P/E
10.55
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
2.56
Price/Book (mrq)
1.81
Enterprise Value/Revenue
1.89
Enterprise Value/EBITDA
5.10
Financial Highlights
Profitability and Income Statement
Profit Margin
8.17%
Return on Assets (ttm)
5.10%
Return on Equity (ttm)
7.26%
Revenue (ttm)
110.99B
Net Income Avi to Common (ttm)
9.06B
Diluted EPS (ttm)
--
Balance Sheet and Cash Flow
Total Cash (mrq)
54.35B
Total Debt/Equity (mrq)
23.06%
Levered Free Cash Flow (ttm)
7.62B